Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agios and Alnylam sign agreement for siRNA candidate
Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).
Hematological Disorders
-
04 Aug 2023
-
15 Mar 2021
Takeda submits New Drug Application for lanadelumab in Japan
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
-
19 Feb 2021
USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment
The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.